NCT00562328View on ClinicalTrials.gov

Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

February 5, 2010

Study Completion Date

December 18, 2014

Conditions
Leukemia
Interventions
BIOLOGICAL

Alemtuzumab

"Week 1 (dose escalation):~Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously~Weeks 2-5:~30mg subcutaneously three times a week."

BIOLOGICAL

Rituximab

"Weeks 2-5:~375 mg/m\^2 by IV once weekly"

BIOLOGICAL

Sargramostim

"Week 1-6:~250 mcg subcutaneously three time as week"

Trial Locations (2)

55905

Mayo Clinic Cancer Center, Rochester

85259-5499

Mayo Clinic Scottsdale, Scottsdale

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT00562328 - Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter